Satisfactory surgical outcome of T2 gastric cancer after modified D2 lymphadenectomy

Abstract

ObjectiveThough D2 lymphadenectomy has been increasingly regarded as standard surgical procedure for advanced gastric cancer (GC), the modified D2 (D1 + 7, 8a and 9) lymphadenectomy may be more suitable than D2 dissection for T2 stage GC. The purpose of this study is to elucidate whether the surgical outcome of modified D2 lymphadenectomy was comparable to that of standard D2 dissection in T2 stage GC patients.MethodsA retrospective cohort study with 77 cases and 77 controls matched for baseline characteristics was conducted. Patients were categorized into two groups according to the extent of lymphadenectomy: the modified D2 group (mD2) and the standard D2 group (D2). Surgical outcome and recurrence date were compared between the two groups.ResultsThe 5-year overall survival (OS) rate was 71.4% for patients accepted mD2 lymphadenectomy and 70.1% for those accepted standard D2, respectively, and the difference was not statistically significant. Multivariate survival analysis revealed that curability, tumor size, TNM stage and postoperative complications were independently prognostic factors for T2 stage GC patients. Patients in the mD2 group tended to have less intraoperative blood loss (P=0.001) and shorter operation time (P<0.001) than those in the D2 group. While there were no significant differences in recurrence rate and types, especially lymph node recurrence, between the two groups.ConclusionsThe surgical outcome of mD2 lymphadenectomy was equal to that of standard D2, and the use of mD2 instead of standard D2 can be a better option for T2 stage GC.

Impact of D2 Gastrectomy for Locally Advanced Gastric Cancer in the Era of Effective Adjuvant Chemotherapy

“…Regarding the frequency of metastasis of each nodal station, our search only identified a report related to T2 gastric cancer from China. Although the frequency of metastasis was rather low, the report showed a similar tendency to our study [12]. The survival rate reported for each nodal station with metastasis was similar to that of the original report by Sasako (although it was an old report from the same institute) [3].…”

Pan-Cancer Analysis of the Characteristics of LY96 in Prognosis and Immunotherapy Across Human Cancer

“…Our research reveals that the LY96 level is upregulated in most cancers, including STAD, COAD, LIHC, and BRCA, which showed higher expression changes relative to normal tissues. Previous studies obtained similar results in gastric cancer ( Zhang et al, 2017 ), colon cancer ( Rajamanickam et al, 2020 ), and hepatocellular cancer ( Qi et al, 2021 ). However, LY96 was downregulated in breast cancer, and LY96 suppression can inhibit cancer development both in vivo and in vitro ( Zhang et al, 2017 ; Zheng et al, 2021 ), which was inconsistent with our result.…”

“…Previous studies obtained similar results in gastric cancer ( Zhang et al, 2017 ), colon cancer ( Rajamanickam et al, 2020 ), and hepatocellular cancer ( Qi et al, 2021 ). However, LY96 was downregulated in breast cancer, and LY96 suppression can inhibit cancer development both in vivo and in vitro ( Zhang et al, 2017 ; Zheng et al, 2021 ), which was inconsistent with our result. These conflicting results may be a reflection of patients with a genetic background or molecular type in breast cancer.…”

Identification of key carcinogenic genes in Wilms’ tumor

“…An association between LY96 and tumorigenesis has been reported by different teams. The dominant impact was mediated by the TLR4 signaling and downstream inflammatory pathways (Hsu et al, 2011;Zhang et al, 2017;Lujan et al, 2018;Zhou et al, 2018). However, the above five risk drivers have not previously been surveyed in WT.…”